- Home
- OBIO vs MSD Comparison
OBIO vs MSD Comparison
Compare OBIO & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- MSD
- Stock Information
- Founded
- OBIO 2017
- MSD 1993
- Country
- OBIO United States
- MSD United States
- Employees
- OBIO N/A
- MSD N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- MSD Trusts Except Educational Religious and Charitable
- Sector
- OBIO Health Care
- MSD Finance
- Exchange
- OBIO Nasdaq
- MSD Nasdaq
- Market Cap
- OBIO 124.9M
- MSD 144.6M
- IPO Year
- OBIO N/A
- MSD N/A
- Fundamental
- Price
- OBIO $3.01
- MSD $7.86
- Analyst Decision
- OBIO Strong Buy
- MSD
- Analyst Count
- OBIO 5
- MSD 0
- Target Price
- OBIO $14.20
- MSD N/A
- AVG Volume (30 Days)
- OBIO 236.8K
- MSD 70.2K
- Earning Date
- OBIO 08-11-2025
- MSD 01-01-0001
- Dividend Yield
- OBIO N/A
- MSD 11.26%
- EPS Growth
- OBIO N/A
- MSD N/A
- EPS
- OBIO N/A
- MSD N/A
- Revenue
- OBIO $2,886,000.00
- MSD N/A
- Revenue This Year
- OBIO $20.47
- MSD N/A
- Revenue Next Year
- OBIO $11.45
- MSD N/A
- P/E Ratio
- OBIO N/A
- MSD N/A
- Revenue Growth
- OBIO 30.23
- MSD N/A
- 52 Week Low
- OBIO $2.37
- MSD $6.11
- 52 Week High
- OBIO $8.87
- MSD $7.46
- Technical
- Relative Strength Index (RSI)
- OBIO 47.82
- MSD 60.54
- Support Level
- OBIO $2.91
- MSD $7.63
- Resistance Level
- OBIO $3.48
- MSD $7.91
- Average True Range (ATR)
- OBIO 0.26
- MSD 0.05
- MACD
- OBIO -0.01
- MSD 0.00
- Stochastic Oscillator
- OBIO 28.78
- MSD 77.79
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.